Viral Gastroenteritis Market

ID: MRFR/HC/3027-HCR
200 Pages
Vikita Thakur
Last Updated: May 15, 2026
Global Viral Gastroenteritis Market Research Report By Type (Norovirus, Rotavirus, Adenovirus, Sapovirus), By Transmission Route (Fecal-Oral Route, Contaminated Water, Contaminated Food), By Age Group (Children, Adults, Elderly), By Treatment Type (Supportive Care, Antiviral Medications, Hydration Solutions) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) -Forecast to 2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Viral Gastroenteritis Market

Market Size

Forecast Period2025 - 2035
CAGR (2025 - 2035)4.24%
2024 Market Size$ 2.22 Billion
2025 Market Size$ 2.31 Billion
2035 Market Size$ 3.5 Billion

Key Players

GSK
Merck & Co.
Pfizer
Sanofi
Bristol-Myers Squibb
Johnson & Johnson
Opportunities
  • Rising Healthcare Expenditure
  • Growing Demand for Preventive Healthcare
  • Impact of Climate Change on Disease Patterns
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Healthcare, BY Type (USD Billion)
      1. 4.1.1 Norovirus
      2. 4.1.2 Rotavirus
      3. 4.1.3 Adenovirus
      4. 4.1.4 Sapovirus
    2. 4.2 Healthcare, BY Transmission Route (USD Billion)
      1. 4.2.1 Fecal-Oral Route
      2. 4.2.2 Contaminated Water
      3. 4.2.3 Contaminated Food
    3. 4.3 Healthcare, BY Age Group (USD Billion)
      1. 4.3.1 Children
      2. 4.3.2 Adults
      3. 4.3.3 Elderly
    4. 4.4 Healthcare, BY Treatment Type (USD Billion)
      1. 4.4.1 Supportive Care
      2. 4.4.2 Antiviral Medications
      3. 4.4.3 Hydration Solutions
    5. 4.5 Healthcare, BY Region (USD Billion)
      1. 4.5.1 North America
        1. 4.5.1.1 US
        2. 4.5.1.2 Canada
      2. 4.5.2 Europe
        1. 4.5.2.1 Germany
        2. 4.5.2.2 UK
        3. 4.5.2.3 France
        4. 4.5.2.4 Russia
        5. 4.5.2.5 Italy
        6. 4.5.2.6 Spain
        7. 4.5.2.7 Rest of Europe
      3. 4.5.3 APAC
        1. 4.5.3.1 China
        2. 4.5.3.2 India
        3. 4.5.3.3 Japan
        4. 4.5.3.4 South Korea
        5. 4.5.3.5 Malaysia
        6. 4.5.3.6 Thailand
        7. 4.5.3.7 Indonesia
        8. 4.5.3.8 Rest of APAC
      4. 4.5.4 South America
        1. 4.5.4.1 Brazil
        2. 4.5.4.2 Mexico
        3. 4.5.4.3 Argentina
        4. 4.5.4.4 Rest of South America
      5. 4.5.5 MEA
        1. 4.5.5.1 GCC Countries
        2. 4.5.5.2 South Africa
        3. 4.5.5.3 Rest of MEA
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Healthcare
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 GSK (GB)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Merck & Co. (US)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Pfizer (US)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Sanofi (FR)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Bristol-Myers Squibb (US)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Johnson & Johnson (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 AbbVie (US)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 AstraZeneca (GB)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 Novartis (CH)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 NORTH AMERICA MARKET ANALYSIS
    3. 6.3 US MARKET ANALYSIS BY TYPE
    4. 6.4 US MARKET ANALYSIS BY TRANSMISSION ROUTE
    5. 6.5 US MARKET ANALYSIS BY AGE GROUP
    6. 6.6 US MARKET ANALYSIS BY TREATMENT TYPE
    7. 6.7 CANADA MARKET ANALYSIS BY TYPE
    8. 6.8 CANADA MARKET ANALYSIS BY TRANSMISSION ROUTE
    9. 6.9 CANADA MARKET ANALYSIS BY AGE GROUP
    10. 6.10 CANADA MARKET ANALYSIS BY TREATMENT TYPE
    11. 6.11 EUROPE MARKET ANALYSIS
    12. 6.12 GERMANY MARKET ANALYSIS BY TYPE
    13. 6.13 GERMANY MARKET ANALYSIS BY TRANSMISSION ROUTE
    14. 6.14 GERMANY MARKET ANALYSIS BY AGE GROUP
    15. 6.15 GERMANY MARKET ANALYSIS BY TREATMENT TYPE
    16. 6.16 UK MARKET ANALYSIS BY TYPE
    17. 6.17 UK MARKET ANALYSIS BY TRANSMISSION ROUTE
    18. 6.18 UK MARKET ANALYSIS BY AGE GROUP
    19. 6.19 UK MARKET ANALYSIS BY TREATMENT TYPE
    20. 6.20 FRANCE MARKET ANALYSIS BY TYPE
    21. 6.21 FRANCE MARKET ANALYSIS BY TRANSMISSION ROUTE
    22. 6.22 FRANCE MARKET ANALYSIS BY AGE GROUP
    23. 6.23 FRANCE MARKET ANALYSIS BY TREATMENT TYPE
    24. 6.24 RUSSIA MARKET ANALYSIS BY TYPE
    25. 6.25 RUSSIA MARKET ANALYSIS BY TRANSMISSION ROUTE
    26. 6.26 RUSSIA MARKET ANALYSIS BY AGE GROUP
    27. 6.27 RUSSIA MARKET ANALYSIS BY TREATMENT TYPE
    28. 6.28 ITALY MARKET ANALYSIS BY TYPE
    29. 6.29 ITALY MARKET ANALYSIS BY TRANSMISSION ROUTE
    30. 6.30 ITALY MARKET ANALYSIS BY AGE GROUP
    31. 6.31 ITALY MARKET ANALYSIS BY TREATMENT TYPE
    32. 6.32 SPAIN MARKET ANALYSIS BY TYPE
    33. 6.33 SPAIN MARKET ANALYSIS BY TRANSMISSION ROUTE
    34. 6.34 SPAIN MARKET ANALYSIS BY AGE GROUP
    35. 6.35 SPAIN MARKET ANALYSIS BY TREATMENT TYPE
    36. 6.36 REST OF EUROPE MARKET ANALYSIS BY TYPE
    37. 6.37 REST OF EUROPE MARKET ANALYSIS BY TRANSMISSION ROUTE
    38. 6.38 REST OF EUROPE MARKET ANALYSIS BY AGE GROUP
    39. 6.39 REST OF EUROPE MARKET ANALYSIS BY TREATMENT TYPE
    40. 6.40 APAC MARKET ANALYSIS
    41. 6.41 CHINA MARKET ANALYSIS BY TYPE
    42. 6.42 CHINA MARKET ANALYSIS BY TRANSMISSION ROUTE
    43. 6.43 CHINA MARKET ANALYSIS BY AGE GROUP
    44. 6.44 CHINA MARKET ANALYSIS BY TREATMENT TYPE
    45. 6.45 INDIA MARKET ANALYSIS BY TYPE
    46. 6.46 INDIA MARKET ANALYSIS BY TRANSMISSION ROUTE
    47. 6.47 INDIA MARKET ANALYSIS BY AGE GROUP
    48. 6.48 INDIA MARKET ANALYSIS BY TREATMENT TYPE
    49. 6.49 JAPAN MARKET ANALYSIS BY TYPE
    50. 6.50 JAPAN MARKET ANALYSIS BY TRANSMISSION ROUTE
    51. 6.51 JAPAN MARKET ANALYSIS BY AGE GROUP
    52. 6.52 JAPAN MARKET ANALYSIS BY TREATMENT TYPE
    53. 6.53 SOUTH KOREA MARKET ANALYSIS BY TYPE
    54. 6.54 SOUTH KOREA MARKET ANALYSIS BY TRANSMISSION ROUTE
    55. 6.55 SOUTH KOREA MARKET ANALYSIS BY AGE GROUP
    56. 6.56 SOUTH KOREA MARKET ANALYSIS BY TREATMENT TYPE
    57. 6.57 MALAYSIA MARKET ANALYSIS BY TYPE
    58. 6.58 MALAYSIA MARKET ANALYSIS BY TRANSMISSION ROUTE
    59. 6.59 MALAYSIA MARKET ANALYSIS BY AGE GROUP
    60. 6.60 MALAYSIA MARKET ANALYSIS BY TREATMENT TYPE
    61. 6.61 THAILAND MARKET ANALYSIS BY TYPE
    62. 6.62 THAILAND MARKET ANALYSIS BY TRANSMISSION ROUTE
    63. 6.63 THAILAND MARKET ANALYSIS BY AGE GROUP
    64. 6.64 THAILAND MARKET ANALYSIS BY TREATMENT TYPE
    65. 6.65 INDONESIA MARKET ANALYSIS BY TYPE
    66. 6.66 INDONESIA MARKET ANALYSIS BY TRANSMISSION ROUTE
    67. 6.67 INDONESIA MARKET ANALYSIS BY AGE GROUP
    68. 6.68 INDONESIA MARKET ANALYSIS BY TREATMENT TYPE
    69. 6.69 REST OF APAC MARKET ANALYSIS BY TYPE
    70. 6.70 REST OF APAC MARKET ANALYSIS BY TRANSMISSION ROUTE
    71. 6.71 REST OF APAC MARKET ANALYSIS BY AGE GROUP
    72. 6.72 REST OF APAC MARKET ANALYSIS BY TREATMENT TYPE
    73. 6.73 SOUTH AMERICA MARKET ANALYSIS
    74. 6.74 BRAZIL MARKET ANALYSIS BY TYPE
    75. 6.75 BRAZIL MARKET ANALYSIS BY TRANSMISSION ROUTE
    76. 6.76 BRAZIL MARKET ANALYSIS BY AGE GROUP
    77. 6.77 BRAZIL MARKET ANALYSIS BY TREATMENT TYPE
    78. 6.78 MEXICO MARKET ANALYSIS BY TYPE
    79. 6.79 MEXICO MARKET ANALYSIS BY TRANSMISSION ROUTE
    80. 6.80 MEXICO MARKET ANALYSIS BY AGE GROUP
    81. 6.81 MEXICO MARKET ANALYSIS BY TREATMENT TYPE
    82. 6.82 ARGENTINA MARKET ANALYSIS BY TYPE
    83. 6.83 ARGENTINA MARKET ANALYSIS BY TRANSMISSION ROUTE
    84. 6.84 ARGENTINA MARKET ANALYSIS BY AGE GROUP
    85. 6.85 ARGENTINA MARKET ANALYSIS BY TREATMENT TYPE
    86. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE
    87. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY TRANSMISSION ROUTE
    88. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY AGE GROUP
    89. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY TREATMENT TYPE
    90. 6.90 MEA MARKET ANALYSIS
    91. 6.91 GCC COUNTRIES MARKET ANALYSIS BY TYPE
    92. 6.92 GCC COUNTRIES MARKET ANALYSIS BY TRANSMISSION ROUTE
    93. 6.93 GCC COUNTRIES MARKET ANALYSIS BY AGE GROUP
    94. 6.94 GCC COUNTRIES MARKET ANALYSIS BY TREATMENT TYPE
    95. 6.95 SOUTH AFRICA MARKET ANALYSIS BY TYPE
    96. 6.96 SOUTH AFRICA MARKET ANALYSIS BY TRANSMISSION ROUTE
    97. 6.97 SOUTH AFRICA MARKET ANALYSIS BY AGE GROUP
    98. 6.98 SOUTH AFRICA MARKET ANALYSIS BY TREATMENT TYPE
    99. 6.99 REST OF MEA MARKET ANALYSIS BY TYPE
    100. 6.100 REST OF MEA MARKET ANALYSIS BY TRANSMISSION ROUTE
    101. 6.101 REST OF MEA MARKET ANALYSIS BY AGE GROUP
    102. 6.102 REST OF MEA MARKET ANALYSIS BY TREATMENT TYPE
    103. 6.103 KEY BUYING CRITERIA OF HEALTHCARE
    104. 6.104 RESEARCH PROCESS OF MRFR
    105. 6.105 DRO ANALYSIS OF HEALTHCARE
    106. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
    107. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    108. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
    109. 6.109 HEALTHCARE, BY TYPE, 2024 (% SHARE)
    110. 6.110 HEALTHCARE, BY TYPE, 2024 TO 2035 (USD Billion)
    111. 6.111 HEALTHCARE, BY TRANSMISSION ROUTE, 2024 (% SHARE)
    112. 6.112 HEALTHCARE, BY TRANSMISSION ROUTE, 2024 TO 2035 (USD Billion)
    113. 6.113 HEALTHCARE, BY AGE GROUP, 2024 (% SHARE)
    114. 6.114 HEALTHCARE, BY AGE GROUP, 2024 TO 2035 (USD Billion)
    115. 6.115 HEALTHCARE, BY TREATMENT TYPE, 2024 (% SHARE)
    116. 6.116 HEALTHCARE, BY TREATMENT TYPE, 2024 TO 2035 (USD Billion)
    117. 6.117 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.2.2 BY TRANSMISSION ROUTE, 2025-2035 (USD Billion)
      3. 7.2.3 BY AGE GROUP, 2025-2035 (USD Billion)
      4. 7.2.4 BY TREATMENT TYPE, 2025-2035 (USD Billion)
    2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
      1. 7.3.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.3.2 BY TRANSMISSION ROUTE, 2025-2035 (USD Billion)
      3. 7.3.3 BY AGE GROUP, 2025-2035 (USD Billion)
      4. 7.3.4 BY TREATMENT TYPE, 2025-2035 (USD Billion)
    3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
      1. 7.4.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.4.2 BY TRANSMISSION ROUTE, 2025-2035 (USD Billion)
      3. 7.4.3 BY AGE GROUP, 2025-2035 (USD Billion)
      4. 7.4.4 BY TREATMENT TYPE, 2025-2035 (USD Billion)
    4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
      1. 7.5.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.5.2 BY TRANSMISSION ROUTE, 2025-2035 (USD Billion)
      3. 7.5.3 BY AGE GROUP, 2025-2035 (USD Billion)
      4. 7.5.4 BY TREATMENT TYPE, 2025-2035 (USD Billion)
    5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
      1. 7.6.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.6.2 BY TRANSMISSION ROUTE, 2025-2035 (USD Billion)
      3. 7.6.3 BY AGE GROUP, 2025-2035 (USD Billion)
      4. 7.6.4 BY TREATMENT TYPE, 2025-2035 (USD Billion)
    6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
      1. 7.7.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.7.2 BY TRANSMISSION ROUTE, 2025-2035 (USD Billion)
      3. 7.7.3 BY AGE GROUP, 2025-2035 (USD Billion)
      4. 7.7.4 BY TREATMENT TYPE, 2025-2035 (USD Billion)
    7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
      1. 7.8.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.8.2 BY TRANSMISSION ROUTE, 2025-2035 (USD Billion)
      3. 7.8.3 BY AGE GROUP, 2025-2035 (USD Billion)
      4. 7.8.4 BY TREATMENT TYPE, 2025-2035 (USD Billion)
    8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
      1. 7.9.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.9.2 BY TRANSMISSION ROUTE, 2025-2035 (USD Billion)
      3. 7.9.3 BY AGE GROUP, 2025-2035 (USD Billion)
      4. 7.9.4 BY TREATMENT TYPE, 2025-2035 (USD Billion)
    9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
      1. 7.10.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.10.2 BY TRANSMISSION ROUTE, 2025-2035 (USD Billion)
      3. 7.10.3 BY AGE GROUP, 2025-2035 (USD Billion)
      4. 7.10.4 BY TREATMENT TYPE, 2025-2035 (USD Billion)
    10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
      1. 7.11.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.11.2 BY TRANSMISSION ROUTE, 2025-2035 (USD Billion)
      3. 7.11.3 BY AGE GROUP, 2025-2035 (USD Billion)
      4. 7.11.4 BY TREATMENT TYPE, 2025-2035 (USD Billion)
    11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
      1. 7.12.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.12.2 BY TRANSMISSION ROUTE, 2025-2035 (USD Billion)
      3. 7.12.3 BY AGE GROUP, 2025-2035 (USD Billion)
      4. 7.12.4 BY TREATMENT TYPE, 2025-2035 (USD Billion)
    12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
      1. 7.13.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.13.2 BY TRANSMISSION ROUTE, 2025-2035 (USD Billion)
      3. 7.13.3 BY AGE GROUP, 2025-2035 (USD Billion)
      4. 7.13.4 BY TREATMENT TYPE, 2025-2035 (USD Billion)
    13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
      1. 7.14.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.14.2 BY TRANSMISSION ROUTE, 2025-2035 (USD Billion)
      3. 7.14.3 BY AGE GROUP, 2025-2035 (USD Billion)
      4. 7.14.4 BY TREATMENT TYPE, 2025-2035 (USD Billion)
    14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
      1. 7.15.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.15.2 BY TRANSMISSION ROUTE, 2025-2035 (USD Billion)
      3. 7.15.3 BY AGE GROUP, 2025-2035 (USD Billion)
      4. 7.15.4 BY TREATMENT TYPE, 2025-2035 (USD Billion)
    15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
      1. 7.16.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.16.2 BY TRANSMISSION ROUTE, 2025-2035 (USD Billion)
      3. 7.16.3 BY AGE GROUP, 2025-2035 (USD Billion)
      4. 7.16.4 BY TREATMENT TYPE, 2025-2035 (USD Billion)
    16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
      1. 7.17.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.17.2 BY TRANSMISSION ROUTE, 2025-2035 (USD Billion)
      3. 7.17.3 BY AGE GROUP, 2025-2035 (USD Billion)
      4. 7.17.4 BY TREATMENT TYPE, 2025-2035 (USD Billion)
    17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
      1. 7.18.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.18.2 BY TRANSMISSION ROUTE, 2025-2035 (USD Billion)
      3. 7.18.3 BY AGE GROUP, 2025-2035 (USD Billion)
      4. 7.18.4 BY TREATMENT TYPE, 2025-2035 (USD Billion)
    18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
      1. 7.19.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.19.2 BY TRANSMISSION ROUTE, 2025-2035 (USD Billion)
      3. 7.19.3 BY AGE GROUP, 2025-2035 (USD Billion)
      4. 7.19.4 BY TREATMENT TYPE, 2025-2035 (USD Billion)
    19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
      1. 7.20.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.20.2 BY TRANSMISSION ROUTE, 2025-2035 (USD Billion)
      3. 7.20.3 BY AGE GROUP, 2025-2035 (USD Billion)
      4. 7.20.4 BY TREATMENT TYPE, 2025-2035 (USD Billion)
    20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
      1. 7.21.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.21.2 BY TRANSMISSION ROUTE, 2025-2035 (USD Billion)
      3. 7.21.3 BY AGE GROUP, 2025-2035 (USD Billion)
      4. 7.21.4 BY TREATMENT TYPE, 2025-2035 (USD Billion)
    21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
      1. 7.22.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.22.2 BY TRANSMISSION ROUTE, 2025-2035 (USD Billion)
      3. 7.22.3 BY AGE GROUP, 2025-2035 (USD Billion)
      4. 7.22.4 BY TREATMENT TYPE, 2025-2035 (USD Billion)
    22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
      1. 7.23.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.23.2 BY TRANSMISSION ROUTE, 2025-2035 (USD Billion)
      3. 7.23.3 BY AGE GROUP, 2025-2035 (USD Billion)
      4. 7.23.4 BY TREATMENT TYPE, 2025-2035 (USD Billion)
    23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
      1. 7.24.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.24.2 BY TRANSMISSION ROUTE, 2025-2035 (USD Billion)
      3. 7.24.3 BY AGE GROUP, 2025-2035 (USD Billion)
      4. 7.24.4 BY TREATMENT TYPE, 2025-2035 (USD Billion)
    24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
      1. 7.25.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.25.2 BY TRANSMISSION ROUTE, 2025-2035 (USD Billion)
      3. 7.25.3 BY AGE GROUP, 2025-2035 (USD Billion)
      4. 7.25.4 BY TREATMENT TYPE, 2025-2035 (USD Billion)
    25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
      1. 7.26.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.26.2 BY TRANSMISSION ROUTE, 2025-2035 (USD Billion)
      3. 7.26.3 BY AGE GROUP, 2025-2035 (USD Billion)
      4. 7.26.4 BY TREATMENT TYPE, 2025-2035 (USD Billion)
    26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
      1. 7.27.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.27.2 BY TRANSMISSION ROUTE, 2025-2035 (USD Billion)
      3. 7.27.3 BY AGE GROUP, 2025-2035 (USD Billion)
      4. 7.27.4 BY TREATMENT TYPE, 2025-2035 (USD Billion)
    27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
      1. 7.28.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.28.2 BY TRANSMISSION ROUTE, 2025-2035 (USD Billion)
      3. 7.28.3 BY AGE GROUP, 2025-2035 (USD Billion)
      4. 7.28.4 BY TREATMENT TYPE, 2025-2035 (USD Billion)
    28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
      1. 7.29.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.29.2 BY TRANSMISSION ROUTE, 2025-2035 (USD Billion)
      3. 7.29.3 BY AGE GROUP, 2025-2035 (USD Billion)
      4. 7.29.4 BY TREATMENT TYPE, 2025-2035 (USD Billion)
    29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
      1. 7.30.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.30.2 BY TRANSMISSION ROUTE, 2025-2035 (USD Billion)
      3. 7.30.3 BY AGE GROUP, 2025-2035 (USD Billion)
      4. 7.30.4 BY TREATMENT TYPE, 2025-2035 (USD Billion)
    30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.31.1
    1. 7.32 ACQUISITION/PARTNERSHIP
  10. 7.32.1

Viral Gastroenteritis Market Segmentation

Viral Gastroenteritis Market By Type (USD Billion, 2025-2035)

  • Norovirus
  • Rotavirus
  • Adenovirus
  • Sapovirus

Viral Gastroenteritis Market By Transmission Route (USD Billion, 2025-2035)

  • Fecal-Oral Route
  • Contaminated Water
  • Contaminated Food

Viral Gastroenteritis Market By Age Group (USD Billion, 2025-2035)

  • Children
  • Adults
  • Elderly

Viral Gastroenteritis Market By Treatment Type (USD Billion, 2025-2035)

  • Supportive Care
  • Antiviral Medications
  • Hydration Solutions